companydata.dkcompanydata.dk

VAR2 PHARMACEUTICALS ApS: Financial statements 2025

CVR: 34621942

Source: annual report 2025, Danish Business Authority

01/01/2025 – 31/12/2025

VAR2 PHARMACEUTICALS ApS (CVR 34621942) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -21,739,014 and a net result of DKK -19,726,508 compared with DKK -21,006,013 the year before. Equity in the 2025 report amounted to DKK 82,032,248. The solvency ratio was 95.7%. The company had 7 employees in the financial year.

Gross Profit
DKK -21,739,014
Profit/Loss
DKK -19,726,508
Equity
DKK 82,032,248
Total Assets
DKK 85,738,763
Employees
7

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2025--21.7 mio.-19.7 mio.82 mio.7
2024--22.7 mio.-21 mio.64.5 mio.8
2023--22.3 mio.-19.1 mio.48.3 mio.6
2022--6.4 mio.-6.8 mio.67.4 mio.5
2021--4.4 mio.-5.9 mio.37 mio.7

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is VAR2 PHARMACEUTICALS ApS?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2025

Tanja Rainer joins the board of VAR2 PHARMACEUTICALS ApSJun 30, 2025

As of June 30, 2025, Tanja Rainer has joined the board of directors of VAR2 PHARMACEUTICALS ApS.

Silviya Stoykova joins the board of VAR2 PHARMACEUTICALS ApSJun 30, 2025

As of June 30, 2025, Silviya Stoykova has joined the board of directors of VAR2 PHARMACEUTICALS ApS.

VAR2 PHARMACEUTICALS ApS: The 2024 annual report is outMay 27, 2025

VAR2 PHARMACEUTICALS ApS has published its annual report for 2024. Gross profit came to DKK -22,697,872, and the net result was DKK -21,006,013.

About VAR2 PHARMACEUTICALS ApS

VAR2 PHARMACEUTICALS ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2012. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Ali El-Salanti and Mads Daugaard. The board consists of Mads Daugaard (chair), Ali El-Salanti, Josef Rainer and Peter Schröcksnadel. The company is owned by ONCOMAL ApS and Københavns Universitet. The company has 10 employees (2026). In 2025, the company reported a gross profit of DKK -21,739,014 and a net result of DKK -19,726,508 compared with DKK -21,006,013 the year before. Equity in the 2025 report amounted to DKK 82,032,248.

Source: annual report 2025, Danish Business Authority